Genenta Receives Nasdaq $1.00 Bid Deficiency Notice; 180 Days to April 14, 2027
GNTA sits 15% above its 52-week low of $0.55.
Summary
Genenta received a Nasdaq notice that its ADSs closed below $1.00 for 30 consecutive business days, giving it until April 14, 2027 to regain compliance, with a previously approved 1-for-10 to 1-for-20 reverse split available as a cure.
Key Events · Legal and Risk Events · GNTA
-
Nasdaq Minimum Bid Deficiency Notice
On October 16, 2026, Nasdaq notified Genenta that its ADS closing bid price was below $1.00 for 30 consecutive business days, from September 3 through October 15, 2026, under Listing Rule 5550(a)(2).
-
180-Day Compliance Window to April 14, 2027
Genenta has until April 14, 2027 to regain compliance, which requires a closing bid of at least $1.00 per ADS for a minimum of 10 consecutive business days; an additional 180-day period may be available if other initial listing standards are met.
-
Reverse Split Available as Cure
Shareholders previously approved a reverse split of 1-for-10 to 1-for-20 on July 29, 2026, and the board is authorized to set the ratio and effective date within 12 months; the company says it may implement it if needed.
-
No Immediate Delisting
The notice has no immediate effect on listing or trading; ADSs continue on the Nasdaq Capital Market under GNTA, subject to continued compliance with other listing requirements.
Analysis · GNTA · Life Sciences
A Nasdaq deficiency letter now puts Genenta on an explicit clock: its ADSs traded below $1.00 for 30 straight business days, and the compliance deadline is April 14, 2027. To cure, the company must hold a $1.00 bid for 10 consecutive business days. It already has shareholder authority for a 1-for-10 to 1-for-20 reverse split that the board can deploy if the price does not recover. Nothing is delisted today, but this is a real listing risk layered on a stock at $0.6352, and a reverse split would be the likely path — which resets the share count and can pressure the price again. Failure to cure by the deadline puts the Nasdaq listing in question.
How filings like this one have moved
In the 30 days to Oct 21, 2026, 37.2% of the 984 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.83%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GNTA was trading at $0.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $29.7M. The 52-week trading range was $0.55 to $10.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.